105 related articles for article (PubMed ID: 6141493)
1. The comparison between enkephalin-like and dynorphin-like immunoreactivity in both monkey and human globus pallidus and substantia nigra.
Haber SN; Watson SJ
Life Sci; 1983; 33 Suppl 1():33-6. PubMed ID: 6141493
[TBL] [Abstract][Full Text] [Related]
2. Possible interactions between dynorphin and dopaminergic systems in rat basal ganglia and substantia nigra.
Quirion R; Gaudreau P; Martel JC; St-Pierre S; Zamir N
Brain Res; 1985 Apr; 331(2):358-62. PubMed ID: 2859094
[TBL] [Abstract][Full Text] [Related]
3. The distribution of dynorphinergic terminals in striatal target regions in comparison to the distribution of substance P-containing and enkephalinergic terminals in monkeys and humans.
Reiner A; Medina L; Haber SN
Neuroscience; 1999; 88(3):775-93. PubMed ID: 10363817
[TBL] [Abstract][Full Text] [Related]
4. Met-enkephalin-like and dynorphin-like immunoreactivities of the basal ganglia of the cat.
Chesselet MF; Graybiel AM
Life Sci; 1983; 33 Suppl 1():37-40. PubMed ID: 6141495
[TBL] [Abstract][Full Text] [Related]
5. Peptides derived from prodynorphin are decreased in basal ganglia of Huntington's disease brains.
Dawbarn D; Zamir N; Waters CM; Hunt SP; Emson PC; Brownstein MJ
Brain Res; 1986 Apr; 372(1):155-8. PubMed ID: 2871898
[TBL] [Abstract][Full Text] [Related]
6. Correlation between Met-enkephalin and substance P immunoreactivity in the primate globus pallidus.
Haber S; Elde R
Neuroscience; 1981; 6(7):1291-7. PubMed ID: 6167897
[No Abstract] [Full Text] [Related]
7. Opioid peptides in Huntington's disease: alterations in prodynorphin and proenkephalin system.
Seizinger BR; Liebisch DC; Kish SJ; Arendt RM; Hornykiewicz O; Herz A
Brain Res; 1986 Jul; 378(2):405-8. PubMed ID: 2873872
[TBL] [Abstract][Full Text] [Related]
8. Primate model of Parkinson's disease: alterations in multiple opioid systems in the basal ganglia.
Zamir N; Skofitsch G; Bannon MJ; Helke CJ; Kopin IJ; Jacobowitz DM
Brain Res; 1984 Nov; 322(2):356-60. PubMed ID: 6150750
[TBL] [Abstract][Full Text] [Related]
9. Light and electron microscopic localization of immunoreactive Leu-enkephalin in the monkey basal ganglia.
DiFiglia M; Aronin N; Martin JB
J Neurosci; 1982 Mar; 2(3):303-20. PubMed ID: 6121017
[No Abstract] [Full Text] [Related]
10. Changes in dynorphin, enkephalin and cholecystokinin content of hippocampus and substantia nigra after amygdala kindling.
Iadarola MJ; Shin C; McNamara JO; Yang HY
Brain Res; 1986 Feb; 365(1):185-91. PubMed ID: 2868784
[TBL] [Abstract][Full Text] [Related]
11. Corticotropin-releasing factor stimulates the release of methionine-enkephalin and dynorphin from the neostriatum and globus pallidus of the rat: in vitro and in vivo studies.
Sirinathsinghji DJ; Nikolarakis KE; Herz A
Brain Res; 1989 Jun; 490(2):276-91. PubMed ID: 2569903
[TBL] [Abstract][Full Text] [Related]
12. [Active peptides in substance P preparations from cortex, globus pallidus and substantia nigra of human brains].
Baldauf J; Harnacke P; Zetler G
Naunyn Schmiedebergs Arch Exp Pathol Pharmakol; 1968; 260(2):231-41. PubMed ID: 4239251
[No Abstract] [Full Text] [Related]
13. Steady state levels of pro-dynorphin-related end products in the striatum and substantia nigra of the adult rhesus monkey.
Dores RM; Akil H
Peptides; 1985; 6 Suppl 2():143-8. PubMed ID: 2867528
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical localization of dynorphin (1-8) in hypothalamic magnocellular neurons: evidence for absence of proenkephalin.
Weber E; Roth KA; Evans CJ; Chang JK; Barchas JD
Life Sci; 1982 Oct 18-25; 31(16-17):1761-4. PubMed ID: 6130434
[TBL] [Abstract][Full Text] [Related]
15. Differential metabolism of dynorphins in substantia nigra, striatum, and hippocampus.
Sandin J; Tan-No K; Kasakov L; Nylander I; Winter A; Silberring J; Terenius L
Peptides; 1997; 18(7):949-56. PubMed ID: 9357051
[TBL] [Abstract][Full Text] [Related]
16. Anterior to posterior variations in the concentration of somatostatin-like immunoreactivity in human basal ganglia.
Davies P; Josef J; Thompson A
Brain Res Bull; 1981 Oct; 7(4):365-8. PubMed ID: 6117352
[TBL] [Abstract][Full Text] [Related]
17. Opiate receptor agonists as modulators of gamma-aminobutyric acid turnover in the nucleus caudatus, globus pallidus and substantia nigra of the rat.
Moroni F; Cheney DL; Peralta E; Costa E
J Pharmacol Exp Ther; 1978 Dec; 207(3):870-7. PubMed ID: 215744
[TBL] [Abstract][Full Text] [Related]
18. Vesicular localization of immunoreactive [Met5]enkephalin in the globus pallidus.
Coulter HD
Proc Natl Acad Sci U S A; 1988 Sep; 85(18):7028-32. PubMed ID: 3413134
[TBL] [Abstract][Full Text] [Related]
19. Immunocytochemical studies of substance P and Met-enkephalin in the basal ganglia and substantia nigra in Huntington's, Parkinson's and Alzheimer's diseases.
Grafe MR; Forno LS; Eng LF
J Neuropathol Exp Neurol; 1985 Jan; 44(1):47-59. PubMed ID: 2578185
[TBL] [Abstract][Full Text] [Related]
20. The distribution of some identified peptide-containing pathways in the central nervous system including the basal ganglia.
Zimmerman EA
Prog Clin Biol Res; 1981; 68():117-25. PubMed ID: 6272328
[No Abstract] [Full Text] [Related]
[Next] [New Search]
